| Literature DB >> 26037622 |
Johannes Hofer1, Thomas Giner1, Gerard Cortina1, Therese Jungraithmayr1, Jurate Masalskiene2, Diana Dobiliene2, Renata Mitkiene2, Birute Pundziene2, Sarunas Rudaitis2.
Abstract
CFH-Ab-associated aHUS requires different diagnostic and therapeutic approaches and then the genetically defined aHUS forms. The risk of post-transplant recurrence with graft dysfunction in CFH-Ab aHUS is not well documented. It is suggested that recurrence can be expected if a significant CFH-Ab load persists at the time of transplantation. A pretransplant procedure to reduce CFH-Ab titer seems reasonable, but accurate recommendations are lacking. Whether further prophylactic interventions after transplantation are necessary has to be decided on an individual basis. We report the case of a late diagnosed CFH-Ab HUS with initial ESRD and a successful living-related renal transplantation over a post-transplant period of four and a half years on the basis of a prophylactic pretransplant IVIG admission.Entities:
Keywords: atypical HUS; complement factor H antibodies; intravenous immunoglobulins; plasma therapy; renal transplantation
Mesh:
Substances:
Year: 2015 PMID: 26037622 DOI: 10.1111/petr.12519
Source DB: PubMed Journal: Pediatr Transplant ISSN: 1397-3142